About Cellusion
Cellusion is a company based in Minato (Japan) founded in 2015. Cellusion has raised $29.71 million across 2 funding rounds from investors including Nikon, Sparx Group and TOHO HOLDINGS. Cellusion operates in a competitive market with competitors including CorneaGen, EyeGate, Avedro, CorNeat Vision and EyeYon, among others.
- Headquarter Minato, Japan
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$29.71 M (USD)
in 2 rounds
-
Latest Funding Round
$20.22 M (USD), Series C
Jun 06, 2023
-
Investors
Nikon
& 12 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cellusion
Cellusion has successfully raised a total of $29.71M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $20.22 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cellusion
Cellusion has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Nikon, Sparx Group and TOHO HOLDINGS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on growth stage companies
|
Locked | Locked | Locked | |
|
Venture capital firm investing in biotech, adtech sectors
|
Locked | Locked | Locked | |
|
Early-stage investments are targeted by Axil Capital, a VC firm.
|
Locked | Locked | Locked |
Investor details for Cellusion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cellusion
Investment portfolio details for Cellusion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cellusion
Detailed financials for Cellusion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellusion Comparisons
Peer comparison for Cellusion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cellusion
Cellusion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CorneaGen, EyeGate, Avedro, CorNeat Vision and EyeYon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic devices for corneal transplants are developed by CorneaGen.
|
|
| Locked | Locked | Locked |
Therapeutics and drug delivery systems for eye diseases are developed.
|
|
| Locked | Locked | Locked |
Corneal collagen cross-linking technology is developed for ophthalmic applications.
|
|
| Locked | Locked | Locked |
Nanotechnology-based artificial corneal implants are developed for ophthalmic use.
|
|
| Locked | Locked | Locked |
Ophthalmic devices for corneal edema treatment are developed.
|
Detailed competitors of Cellusion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellusion
Complete news archive for Cellusion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellusion
Cellusion was founded in 2015 and raised its 1st funding round 7 years after it was founded.
Cellusion is headquartered in Minato, Japan. It is registered at Minato, Tokyo, Japan.
Shin Hatou is the current CEO of Cellusion.
Cellusion is a funded company, having raised a total of $29.71M across 2 funding rounds to date.
Cellusion was founded in 2015 and is based in Minato City, Japan. Operations are centered in the biotechnology sector, with a focus on regenerative medicine. iPS cell-derived materials are developed for transplantation to replace damaged corneal endothelium. This approach is applied to treat bullous keratopathy through direct injection into the cornea, supporting clinical advancements in ocular therapies.
Cellusion has 13 investors. Key investors include Nikon, Sparx Group, TOHO HOLDINGS, Keio Innovation Initiative, and Toyo Seikan Kaisha.